Empty Bowls fundraiser at Binghamton General tomorrow
This afternoon marked the 19th annual Empty Bowls lunch event.
The public was invited to UHS Medical Center in Johnson City for a catered lunch of pasta, soups, burgers, desserts and more, to raise money for the Food Bank of the Southern Tier.
Those who attended also got to select a handcrafted bowl of their choice, as a keepsake, and reminder of food insecurity in our community.
The Corporate Partnerships Manager at the Food Bank, Maddy McClenahan, says if you missed out today, there will be another lunch event at Binghamton General, tomorrow from 11:30 to 1:30.
'It's a great opportunity to connect with people who care about food insecurity and food brings people together. So, it's just a great way to get together over some delicious food, meet new people, and do good,' says McClenahan.
Tickets for tomorrow's event are $25 and a portion of the funds raised will support the UHS Foundation's STOP Hunger Fund and the Food Bank.
You can purchase tickets at NYUHS.org/events.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31-07-2025
- Yahoo
UHS posts softer-than-expected volumes for second consecutive quarter
This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Dive Brief: Certain Universal Health Services growth targets for 2025 are looking less achievable after the for-profit health system reported another quarter of lackluster admissions on Monday. Behavioral health volumes in the second quarter were essentially flat, with adjusted admissions rising just 0.4%. It's an improvement from last quarter, when behavioral health volumes declined. However, executives now consider UHS' plans to grow adjusted behavioral patient days by 2.5% to 3% a long-term target, instead of a 2025 goal. CEO Marc Miller said one of the reasons UHS' patient day target has remained 'elusive' is payers' growing preference for outpatient care, a trend that hasn't favored UHS' inpatient-heavy portfolio. To be competitive in the long term, UHS plans to focus capital spending on outpatient projects, building 10 to 15 freestanding behavioral health facilities per year. Dive Insight: UHS raised the midpoint of its 2025 guidance after posting $353.2 million in net income on $4.3 billion in revenue in the second quarter. The King of Prussia, Pennsylvania-based provider now expects to take in between $17.09 billion and $17.31 billion in revenue this year, compared to its prior range of between $17.02 billion and $17.36 billion. UHS attributed the change to the approval of a Medicaid state supplemental payment program in Tennessee, which accounted for roughly $101 million of the system's guidance raise, and the opening of West Henderson Hospital in Las Vegas. However, problems receiving Medicaid certification and other start-up issues in its newly opened Cedar Hill Regional Medical Center in Washington, D.C., tempered the guidance increase by about $25 million, CFO Steve Filton said on a Tuesday call with investors. The modest lift in UHS' financial forecast was mostly overshadowed by investor concerns about the operator's volumes. UHS' acute care unit didn't fare much better than behavioral, with adjusted admissions rising just 2% and surgical volumes 'slightly' down year over year, according to Filton. The modest growth in both behavioral and acute volumes underperformed analysts' expectations, according to a Tuesday note from Morgan Stanley. Executives blamed lower volumes on numerous factors including staffing challenges, as well as the slower-than-expected opening at Cedar Hills. UHS' behavioral business has also suffered from payers shifting care to cheaper outpatient sides, a trend that's proved tricky for the company as it's historically focused on inpatient care. UHS is the latest health system to report poorer-than-expected patient volumes during the second quarter, though health systems disagree on the reason behind the trend. CHS said consumers are less interested in spending on healthcare in an unstable economy, HCA blamed slow growth in public payer programs and Tenet brushed it off as a product of seasonal changes. UHS said it hopes to ultimately capture more volumes by opening behavioral centers and referring more inpatient cases to UHS outpatient providers for so-called 'step-down' services. 'A number of the insurance companies, as they have been talking about their increase in medical loss ratios, have pointed to the increase in spending on behavioral care,' Filton said. 'We believe that a significant chunk of that increase is in outpatient, and we are determined to get a larger share of that, I'll call it, 'outpatient pie' as we go forward.' Executives also commented on how the recently passed 'Big Beautiful Bill' will impact UHS' business over the coming years. Starting in 2028, the federal government will cap provider taxes and state directed payments in Medicaid, which previously have boosted the health system's revenue. UHS said the changes could cost it between $300 to $400 million by 2032 if the law is carried out as currently outlined. Miller cautioned that this is a worst case scenario and one he hopes to avoid. 'In talking with all the folks in D.C., representatives from many of the states we cover, they are starting to recognize what they passed can't be left as is because of the effect on some of the healthcare programs in their state,' he said. Still, Filton said that UHS will be ready for potential changes, noting the company weathered similar headwinds during the COVID-19 pandemic. The CFO said UHS would consider headcount reductions and other spending cuts if necessary. 'We have great confidence in our ability to shift and be flexible, especially with several years of notice and preparation that we'll have this time around,' Filton said. Recommended Reading Tenet's net income tumbled in Q3
Yahoo
31-07-2025
- Yahoo
Cancer blood test trial gives fresh hope to patients and families
A cancer blood test trial is giving fresh hope to patients and families. The MODERNISED study, currently running in Dorset, has recruited more than 450 participants as it evaluates a new blood test designed to detect multiple cancers at their earliest stages. Unlike other tests in development, the technology being trialled identifies immune system responses to cancer rather than relying on DNA markers. The test is also being assessed for its ability to pinpoint the type of cancer detected. The study is taking place at five hospitals across the UK, including University Hospitals Dorset and Dorset County Hospital. It is led by researchers in Southampton in collaboration with the Southampton Clinical Trials Unit and Proteotype Diagnostics Ltd. The trial is funded by the National Institute for Health and Care Research (NIHR) Invention for Innovation programme and the Office for Life Sciences. READ: Breakthrough blood test trial for dementia diagnosis begins in Dorset Ian Robinson taking part in MODERNISED at UHS. Ian Robinson, 72, who was diagnosed with colorectal cancer following routine screening, is among those taking part in the study. Mr Robinson said: "I was sent the NHS bowel cancer screening kit. "I think I had done four of these, normally with a negative result, but the most recent one indicated that there was a chance of cancer which was confirmed with a colonoscopy. "There were no symptoms, no pain, nothing, so you would never know until it was much more advanced and therefore much more difficult to treat." He said he was pleased to take part in the trial. Mr Robinson said: "Obviously the team here is helping me, so I'm delighted to participate and hopefully help improve the way things are done. "My mother died from cancer. I now have children and five grandchildren, so yes, research is absolutely vital. "The more cancers that can be identified as early as possible, that can benefit future generations, then it's obviously the right way to go." READ: Dorset charity helps woman to fund potentially life-extending cancer drug Victoria Goss, associate professor and head of Early Diagnosis Research at the Southampton Clinical Trials Unit. (Image: UHS) Each year, around 385,000 people in the UK are diagnosed with cancer. Dr Victoria Goss, associate professor and head of early diagnosis research at the Southampton Clinical Trials Unit, said: "When cancers are diagnosed later, there are often fewer treatment options available to patients. "Detecting cancer early means that treatment can begin sooner, increasing the chances of successful outcomes for patients. "Improving early diagnosis is therefore a priority for us as researchers and for the NHS. "But currently there are only four screening programmes in the UK and screening is only for one cancer at a time, so we are aiming to develop simple tests that can potentially pick up the signs of multiple cancers, giving the best possible chance of early, successful treatment." READ: Walkers raise over £900k for Macmillan Cancer Support Prof Andy Davies. (Image: UHS) The study is led by Professor Andy Davies, director of the Southampton Cancer Research UK and NIHR Experimental Cancer Medicine Centre. Professor Davies said: "Most current research into multi-cancer blood tests is focussed on detecting abnormal DNA that has been released into the blood stream by cancer cells. "But this circulating tumour DNA cannot always be detected in the very early stages of cancer. "We are instead looking at levels of certain proteins found in blood. "We know that even in the earliest stages of cancer, the body's immune response can lead to higher levels of these proteins being released, and we believe these may be a good way to test for early signs of the disease."
Yahoo
28-07-2025
- Yahoo
Universal Health Services's (NYSE:UHS) Q2 Sales Beat Estimates
Hospital management company Universal Health Services (NYSE:UHS) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 9.6% year on year to $4.28 billion. The company expects the full year's revenue to be around $17.2 billion, close to analysts' estimates. Its non-GAAP profit of $5.35 per share was 8.4% above analysts' consensus estimates. Is now the time to buy Universal Health Services? Find out in our full research report. Universal Health Services (UHS) Q2 CY2025 Highlights: Revenue: $4.28 billion vs analyst estimates of $4.24 billion (9.6% year-on-year growth, 1% beat) Adjusted EPS: $5.35 vs analyst estimates of $4.94 (8.4% beat) Adjusted EBITDA: $642.9 million vs analyst estimates of $619.4 million (15% margin, 3.8% beat) Adjusted EPS guidance for the full year is $20 at the midpoint, beating analyst estimates by 1.9% EBITDA guidance for the full year is $2.50 billion at the midpoint, above analyst estimates of $2.47 billion Operating Margin: 11.7%, in line with the same quarter last year Free Cash Flow Margin: 6.6%, down from 11.2% in the same quarter last year Same-Store Sales were flat year on year (3.4% in the same quarter last year) Market Capitalization: $10.03 billion Company Overview With a network spanning 39 states and three countries, Universal Health Services (NYSE:UHS) operates acute care hospitals and behavioral health facilities across the United States, United Kingdom, and Puerto Rico. Revenue Growth Reviewing a company's long-term sales performance reveals insights into its quality. Any business can have short-term success, but a top-tier one grows for years. Thankfully, Universal Health Services's 7.9% annualized revenue growth over the last five years was decent. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Universal Health Services's annualized revenue growth of 9.2% over the last two years is above its five-year trend, suggesting some bright spots. We can dig further into the company's revenue dynamics by analyzing its same-store sales, which show how much revenue its established locations generate. Over the last two years, Universal Health Services's same-store sales averaged 3.4% year-on-year growth. Because this number is lower than its revenue growth, we can see the opening of new locations is boosting the company's top-line performance. This quarter, Universal Health Services reported year-on-year revenue growth of 9.6%, and its $4.28 billion of revenue exceeded Wall Street's estimates by 1%. Looking ahead, sell-side analysts expect revenue to grow 6.8% over the next 12 months, a slight deceleration versus the last two years. We still think its growth trajectory is satisfactory given its scale and indicates the market is forecasting success for its products and services. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin Universal Health Services was profitable over the last five years but held back by its large cost base. Its average operating margin of 9.8% was weak for a healthcare business. Looking at the trend in its profitability, Universal Health Services's operating margin decreased by 1.3 percentage points over the last five years, but it rose by 3.1 percentage points on a two-year basis. Still, shareholders will want to see Universal Health Services become more profitable in the future. In Q2, Universal Health Services generated an operating margin profit margin of 11.7%, in line with the same quarter last year. This indicates the company's overall cost structure has been relatively stable. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Universal Health Services's EPS grew at a spectacular 14.7% compounded annual growth rate over the last five years, higher than its 7.9% annualized revenue growth. However, this alone doesn't tell us much about its business quality because its operating margin didn't improve. Diving into Universal Health Services's quality of earnings can give us a better understanding of its performance. A five-year view shows that Universal Health Services has repurchased its stock, shrinking its share count by 23.6%. This tells us its EPS outperformed its revenue not because of increased operational efficiency but financial engineering, as buybacks boost per share earnings. In Q2, Universal Health Services reported EPS at $5.35, up from $4.31 in the same quarter last year. This print beat analysts' estimates by 8.4%. Over the next 12 months, Wall Street expects Universal Health Services's full-year EPS of $18.82 to grow 8.1%. Key Takeaways from Universal Health Services's Q2 Results It was encouraging to see Universal Health Services beat analysts' full-year EPS and EBITDA guidance expectations. We were also happy its revenue, EPS, and EBITDA outperformed Wall Street's estimates despite missing on same-store sales. Zooming out, we think this was a good quarter. The stock remained flat at $154.70 immediately after reporting. So do we think Universal Health Services is an attractive buy at the current price? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
